Findings also differed by agent: cyclophosphamide and doxorubicin showed a trend opposite toward an increased CIHL risk, methotrexate showed no effect, and ifosfamide demonstrated an association with increased CIHL risk.
← all excerpts
Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.
1
—
—